These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 16670073

  • 1. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma.
    Visco C, Canal F, Parolini C, Andreoli A, Ambrosetti A, Krampera M, Lestani M, Pizzolo G, Chilosi M.
    Haematologica; 2006 May; 91(5):687-90. PubMed ID: 16670073
    [Abstract] [Full Text] [Related]

  • 2. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
    Paik JH, Jeon YK, Park SS, Kim YA, Kim JE, Huh J, Lee SS, Kim WH, Kim CW.
    Histopathology; 2005 Sep; 47(3):281-91. PubMed ID: 16115229
    [Abstract] [Full Text] [Related]

  • 3. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Ståhl E, Nordic Lymphoma Group study.
    Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
    [Abstract] [Full Text] [Related]

  • 4. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 5. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, Prat J, Sierra J.
    Ann Hematol; 2006 Sep 01; 85(9):597-603. PubMed ID: 16830142
    [Abstract] [Full Text] [Related]

  • 6. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.
    Eur J Haematol; 2009 May 01; 82(5):364-72. PubMed ID: 19141121
    [Abstract] [Full Text] [Related]

  • 7. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.
    J Clin Oncol; 2008 Jan 20; 26(3):447-54. PubMed ID: 18086797
    [Abstract] [Full Text] [Related]

  • 8. Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
    Kyllönen H, Pasanen AK, Kuittinen O, Haapasaari KM, Turpeenniemi-Hujanen T.
    Leuk Lymphoma; 2009 Aug 20; 50(8):1301-7. PubMed ID: 19811332
    [Abstract] [Full Text] [Related]

  • 9. Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma.
    Nyman H, Jantunen E, Juvonen E, Elonen E, Böhm J, Kosma VM, Enblad G, Karjalainen-Lindsberg ML, Leppä S.
    Bone Marrow Transplant; 2008 Jul 20; 42(2):93-8. PubMed ID: 18391989
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups.
    Br J Haematol; 2008 Feb 20; 140(4):411-9. PubMed ID: 18162120
    [Abstract] [Full Text] [Related]

  • 11. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
    van Galen JC, Muris JJ, Giroth CP, Vos W, Ossenkoppele GJ, Meijer CJ, Oudejans JJ.
    Histopathology; 2008 Apr 20; 52(5):578-84. PubMed ID: 18312353
    [Abstract] [Full Text] [Related]

  • 12. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains.
    Yahalom J.
    J Clin Oncol; 2010 Sep 20; 28(27):4105-7. PubMed ID: 20713874
    [No Abstract] [Full Text] [Related]

  • 13. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma.
    Møller MB, Gerdes AM, Skjødt K, Mortensen LS, Pedersen NT.
    Clin Cancer Res; 1999 May 20; 5(5):1085-91. PubMed ID: 10353742
    [Abstract] [Full Text] [Related]

  • 14. pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
    Stewart DA, Bahlis N, Mansoor A.
    Leuk Lymphoma; 2009 Aug 20; 50(8):1276-82. PubMed ID: 19562614
    [Abstract] [Full Text] [Related]

  • 15. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D, Sebban C, Boulat O, Biron P, Rey J, Aurran T, Chabannon C, Xerri L, Chetaille B, Esterni B, Ivanov V, Stoppa AM, Schiano de Collela JM, Gastaut JA, Maraninchi D, Bouabdallah R.
    Bone Marrow Transplant; 2006 Aug 20; 38(3):217-22. PubMed ID: 16770316
    [Abstract] [Full Text] [Related]

  • 16. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.
    Eur J Haematol; 2008 Dec 20; 81(6):448-53. PubMed ID: 18691256
    [Abstract] [Full Text] [Related]

  • 17. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.
    Ai Zheng; 2006 Dec 20; 25(12):1543-9. PubMed ID: 17166383
    [Abstract] [Full Text] [Related]

  • 18. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
    Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, Kang MJ, Lee DG, Kim HS, Shim H, Moon WS.
    Am J Surg Pathol; 2008 Oct 20; 32(10):1523-31. PubMed ID: 18724249
    [Abstract] [Full Text] [Related]

  • 19. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype.
    Heyning FH, Hogendoorn PC, Kramer MH, Holland CT, Dreef E, Jansen PM.
    J Clin Pathol; 2009 Sep 20; 62(9):820-4. PubMed ID: 19734480
    [Abstract] [Full Text] [Related]

  • 20. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis.
    Ballonoff A, Rusthoven KE, Schwer A, McCammon R, Kavanagh B, Bassetti M, Newman F, Rabinovitch R.
    Int J Radiat Oncol Biol Phys; 2008 Dec 01; 72(5):1465-71. PubMed ID: 18495371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.